
GSK has agreed to buy a pharmaceutical firm that is developing treatment for people with food allergies in a deal valued at 2.2 billion US dollars (£1.6 billion).
The London-listed company said the acquisition of Rapt Therapeutics includes ozureprubart, an antibody currently in phase two clinical development for prophylactic protection against food allergens.